296 (6): E1183E1194
Phase 2b ACCESS Study of Aleniglipron in Adults with Obesity or Overweight , published in Press release (Structure Therapeutics) (Structure Therapeutics investigators, 2025): ACCESS II Exploratory Study of Higher-Dose Aleniglipron , published in Press release (Structure Therapeutics) (Structure Therapeutics investigators, 2025): We summarize new studies, safety updates, and dosing insights delivered biweekly
The most common side effects include nausea, diarrhea, constipation, headache, vomiting, and low blood sugar
In prior studies we quantified H2AX foci per nucleus as a function of radiation dose and corresponding stimulated saliva secretion data at 12 weeks post-irradiation which is the gold standard test for radioprotection 51
The major benefit is when you're going to take it early on because it's going to allow your body to increase blood flow to the injured area and the less blood flow it has